LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

LLY

1,102.5

+0.95%↑

JNJ

207.31

+0.22%↑

ABBV

227.86

-1.85%↓

UNH

330.44

+1.66%↑

AZN

93.65

+0.84%↑

Search

Ascendis Pharma A-S ADR

Abierto

SectorSalud

210.09 2.87

Resumen

Variación precio

24h

Actual

Mínimo

202.45

Máximo

217.48

Métricas clave

By Trading Economics

Ingresos

-22M

-61M

Ventas

56M

214M

Margen de beneficio

-28.549

Empleados

1,017

EBITDA

-56M

-53M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+24.46% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

902M

13B

Apertura anterior

207.22

Cierre anterior

210.09

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

167 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 nov 2025, 16:56 UTC

Ganancias
Principales Movimientos del Mercado

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25 nov 2025, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 nov 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25 nov 2025, 22:39 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 nov 2025, 22:39 UTC

Charlas de Mercado

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25 nov 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 nov 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

25 nov 2025, 21:38 UTC

Ganancias

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 nov 2025, 21:31 UTC

Charlas de Mercado

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25 nov 2025, 21:27 UTC

Ganancias

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25 nov 2025, 21:20 UTC

Ganancias

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 nov 2025, 21:18 UTC

Ganancias

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25 nov 2025, 21:15 UTC

Ganancias

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 nov 2025, 20:16 UTC

Charlas de Mercado

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25 nov 2025, 18:42 UTC

Charlas de Mercado

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25 nov 2025, 18:25 UTC

Adquisiciones, fusiones, absorciones

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25 nov 2025, 17:30 UTC

Charlas de Mercado

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25 nov 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 nov 2025, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

25 nov 2025, 16:33 UTC

Adquisiciones, fusiones, absorciones

Eni: Financial Details Weren't Disclosed

25 nov 2025, 16:33 UTC

Adquisiciones, fusiones, absorciones

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25 nov 2025, 16:32 UTC

Adquisiciones, fusiones, absorciones

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25 nov 2025, 16:31 UTC

Adquisiciones, fusiones, absorciones

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25 nov 2025, 16:30 UTC

Adquisiciones, fusiones, absorciones

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25 nov 2025, 16:23 UTC

Ganancias

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25 nov 2025, 16:12 UTC

Charlas de Mercado

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25 nov 2025, 16:11 UTC

Charlas de Mercado

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25 nov 2025, 16:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 nov 2025, 16:10 UTC

Charlas de Mercado

Sterling Could Briefly Rise After Budget -- Market Talk

25 nov 2025, 16:10 UTC

Charlas de Mercado

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

24.46% repunte

Estimación a 12 meses

Media 260.15 USD  24.46%

Máximo 325 USD

Mínimo 220 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

14

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Strong Bullish Evidence

Sentimiento

By Acuity

167 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat